ERBB2 and pancreatic neoplasm: Most pancreatic carcinomas (95%) aberrantly express EGFR, HER2 and HER3 receptors and their cognate ligands, promoting constitutive activation of EGFR family members that result in pancreatic cancer cell proliferation [39, 40].